Eva Ellebaek

Copenhagen University Hospital

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (9)

Jens Folke Kiilgaard

Københavns Universitet

DENMARK

View details

Christian Rønn Hansen

Odense University Hospital

DENMARK

View details

Christina H Ruhlmann

Associate Professor

University of Southern Denmark

DENMARK

View details

Christian von Buchwald

Professor, mD, DMSc

Rigshospitalet

DENMARK

View details

Henrik Vedel Nielsen

Head of Laboratory, Parasitology

Statens Serum Institut

DENMARK

View details

Henrik Schmidt

Consultant, Ass. Prof

Aarhus University Hospital

DENMARK

View details

Jacob Bjerrum

Consultant Gastroenterologist and Associate Professor

Herlev Hospital

DENMARK

View details

Carsten Faber

Copenhagen University Hospital

DENMARK

View details

Inge Marie Svane

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eva Ellebaek

Research Interests

Explore related searches

Contact this professor

Articles (21)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

Durable Complete Response after Combined Treatment with Tumor-Infiltrating Lymphocytes and Oncolytic Adenovirus (TILT-123) in a Patient with Metastatic Mucosal Melanoma

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study

Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

Clinical value of routine [18F]2‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.

Collaborators (9)

Jens Folke Kiilgaard

Christian Rønn Hansen

Christina H Ruhlmann

Christian von Buchwald

Henrik Vedel Nielsen

Henrik Schmidt

Jacob Bjerrum

Carsten Faber

Inge Marie Svane

Make your next move.